Status:

WITHDRAWN

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Lead Sponsor:

Eli Lilly and Company

Conditions:

Obesity

Overweight

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabet...

Eligibility Criteria

Inclusion

  • Have type 2 diabetes
  • Have a BMI of ≥27 kilograms per square meter (kg/m2)
  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Exclusion

  • Have a prior or planned surgical treatment for obesity,
  • Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma
  • Have poorly controlled hypertension
  • Have any of the following cardiovascular conditions within 3 months prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
  • Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
  • Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
  • Have renal impairment
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease
  • Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
  • Have a history of acute or chronic pancreatitis
  • Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Key Trial Info

Start Date :

May 23 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 10 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06901349

Start Date

May 23 2025

End Date

June 10 2025

Last Update

September 24 2025

Active Locations (50)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (50 locations)

1

Yuma Clinical Trials

Yuma, Arizona, United States, 85364

2

Orange County Research Center

Lake Forest, California, United States, 92630

3

Healthy Brain Clinic

Long Beach, California, United States, 90804

4

Valley Clinical Trials, Inc.

Northridge, California, United States, 91325

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | DecenTrialz